Isospaglumic acid
Source Isospaglumic acid at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Isospaglumic acid (N‑acetylaspartylglutamic acid) is mentioned in a 1993 review as a mast‑cell stabiliser considered for topical use in seasonal allergic rhinitis. It is proposed to be part of an individualized treatment strategy that combines allergen avoidance, topical corticosteroids, antihistamines and immunotherapy, aiming to reduce the inflammatory response that underlies nasal allergy symptoms.
Mechanism of Action
According to the cited review, isospaglumic acid functions as a mast‑cell stabiliser. By preventing mast‑cell degranulation, it limits the release of histamine, leukotrienes and other inflammatory mediators that drive the nasal inflammation of allergic rhinitis. This stabilising effect is described as impairing the destructive activity of allergic inflammation, although the precise cellular pathways are not detailed in the source.
What the Research Shows
The only source referencing isospaglumic acid is a 1993 narrative review of newer treatment approaches for seasonal allergic rhinitis. The author lists it alongside cromolyn sodium and nedocromil as a topical mast‑cell stabiliser with potency to curb allergic inflammation. No original clinical trials, comparative studies, or quantitative efficacy data are presented; the discussion is based on expert opinion and the broader understanding of mast‑cell stabilisers at that time. Consequently, the evidence base for isospaglumic acid remains limited to this descriptive mention.
Reported Benefits
The review suggests that, when applied topically, isospaglumic acid may help reduce nasal symptoms by stabilising mast cells and limiting mediator release. In theory, this could complement other agents such as intranasal corticosteroids or antihistamines, offering a non‑sedating option that targets an early step in the allergic cascade. However, the benefit claim is inferred from its class rather than demonstrated in specific studies.
Limitations of the Evidence
Evidence for isospaglumic acid is confined to a single narrative review; no controlled trials, dose‑response data, or comparative effectiveness studies are cited. Its regulatory status, optimal formulation, and clinical potency relative to other mast‑cell stabilisers are not addressed. The lack of quantitative outcomes makes it impossible to gauge real‑world efficacy or to compare it with established agents such as cromolyn sodium or nedocromil.
Safety Considerations
The abstract does not provide information on adverse effects or safety monitoring for isospaglumic acid. Mast‑cell stabilisers are generally regarded as having low systemic absorption and a favorable tolerability profile when used topically, but specific safety data for isospaglumic acid are absent from the source. Caution is warranted until formal safety assessments are available.
How It Is Administered
Isospaglumic acid is described only as a topical agent for allergic rhinitis, implying use as a nasal spray, drops, or similar intranasal formulation. No details on concentration, dosing frequency, or vehicle are provided in the cited literature.
Routes of Administration
No administration routes recorded yet.
Goals & Uses
No goal associations recorded yet.
Contraindications
No contraindications recorded yet.
Adverse Effects
No adverse effects recorded yet.
Drug Interactions
No drug interactions recorded yet.
Population Constraints
No population constraints recorded yet.
Regulatory Status
No regulatory status recorded yet.
Evidence & Sources
- Journal ArticleModerateHorak F1993-01-01T00:00:00.000000Z
Frequently Asked Questions
What type of drug is isospaglumic acid?
Isospaglumic acid is identified as a mast‑cell stabiliser, a class of compounds that aim to prevent mast‑cell degranulation and the subsequent release of inflammatory mediators in allergic conditions.
How is isospaglumic acid thought to work in allergic rhinitis?
By stabilising mast cells in the nasal mucosa, the drug is intended to reduce the release of histamine and other mediators that cause nasal congestion, itching, and sneezing, thereby attenuating the allergic inflammatory response.
Is isospaglumic acid approved for treating allergic rhinitis?
The cited review does not mention any regulatory approval; its status is described only as a newer topical option under discussion, with no indication of formal licensure for allergic rhinitis.
What evidence supports its use?
The only evidence cited is a 1993 expert review that lists isospaglumic acid among mast‑cell stabilisers with potential potency. No clinical trial data, efficacy measurements, or comparative studies are provided.
Are there known side effects?
The source does not report specific adverse effects for isospaglumic acid. While mast‑cell stabilisers are generally well tolerated when applied locally, safety information for this particular compound remains unavailable.
What is Isospaglumic acid?
Isospaglumic acid (N‑acetylaspartylglutamic acid) is mentioned in a 1993 review as a mast‑cell stabiliser considered for topical use in seasonal allergic rhinitis. It is proposed to be part of an individualized treatment strategy that combines allergen avoidance, topical corticosteroids, antihistamines and immunotherapy, aiming to reduce the inflammatory response that underlies nasal allergy symptoms.